tbuckley/cabot-search huggingface dataset:
AB0470 Serological Evolution in Fertile Women with Positive Antiphospholipid Antibodies
Authors: L. Riancho-Zarrabeitia, G. Daroca, M. Lόpez Hoyos, P. Muñoz, A. Haya, M. González, R. Del Barrio, V. Martínez-Taboada
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of aPL and at least a clinical event defined as recurrent venous thrombosis, arterial thombosis or pregnancy morbidity. The titers of aPL usually fluctuate, they frequently decrease and eventually become negative during follow-up period, thus reducing the risk of thrombotic events. <h3>Objectives</h3> The aim of this study was to explore the clinical and serological course of fertile women with positive aPL, as well as the factors and the potential therapeutic implications associated with aPL negativization. <h3>Methods</h3> We conducted a retrospective study including women attending the obstetric autoimmune pathology clinic of a tertiary-facility serving a population in about 350,000 in Northern Spain. We included 105 women with a confirmed positive APL serology according to Sydney Criteria between October 1995 and December 2013. Patients were classified into 3 different groups: A) patients with primary APS (49), B) patients with a positive serology for APL, not meeting clinical criteria (42) and C) patients with systemic lupus erythematosus and a positive serology for APS (14). They were also classified, according to the serological APL evolution: patients with persistently negative aPL, transiently positive serology and persistently positive serology according to previously established criteria. <h3>Results</h3> After a mean follow up of 114,4±37,2 months, 59% patients had persistently negative antibodies, while 25,7% patients presented persistently positive aPL serology. After the multivariate analysis only the tobacco use (OR 3,5 p=0,013) was confirmed as an independent risk factor. The load of antibodies, specially the presence of triple positivity (OR: 2,4; IC: 0,16–2,36), was close to statistical significance (p=0,162). No other factors, including traditional cardiovascular risk factors, treatments or clinical manifestations reached statistical significance. Persistent positivity was associated with higher risk for further pregnancy morbidity (41 vs 52%; p=0,328). In 17 patients, with persistently negative serology who were asymptomatic, treatment with low dose aspirin was discontinued. No clinical events related to APS were reported after treatment withdrawal, during a 119,9 months follow-up period. <h3>Conclusions</h3> Our study suggests that among fertile women, antiphospholipid antibodies remain persistently positive only in one quarter of patients, being tobacco use an independent risk factors for its persistence. Among patients with persistently negative serology and with a low-risk profile discontinuation of antiplatelet therapy could be considered a safe choice. <h3>Disclosure of Interest</h3> None declared
Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist,
Authors: Alice Y Shih, Annelie Schairer, Christian L Barrett, Ifat Geron, Angela C Court Recart, Daniel Goff, Sacha Prashad, Jerry Wu, Qingfei Jiang, Jason Gotlib, Larisa Balaian, Mark D. Minden, Heather Leu, Russell Wall, Wenxue Ma, Kamran Shazand, John D McPherson, Steven M. Kornblau, Ida Deichaite, Minya Pu, Lei Bao, Giovanni Martinelli, Tannishtha Reya, Sheldon R Morris, Todd VanArsdale, Thomas J Hudson, Karen Messer, Hanna Mikkola, Wendy J. Levin, Kelly A Frazer, Anil Sadarangani, Catriona Jamieson
Journal: Blood (2011)
Towards a New Therapy for Hemophilia A: Evaluation of Multiple Approaches To Prolong the In Vivo Efficacy of Recombinant Factor VIII.
Authors: John E. Murphy, Clark Pan, Baisong Mei, Jonathan Strauss, Hendri Tjandra, Liang Tang, Pamela Esmon, James Newgren, Gary Jesmok, Kyle Landskroner, Mohan Parmathi, Klaus-Peter Radtke, Joanne Severs, John Teare, Haiyan Jiang, Michael Fournel
Journal: Blood (2006)
Mutation Status of Imatinib Mesylate-Resistants CML Patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMC Group.
Authors: Selim Corm, Franck Nicollini, Dominique Borie, Nathalie Sorel, Thibault Leguay, Sandrine Hayette, Thierry Facon, Laurence Roy, Stephane Giraudier, Gerald Marit, Claude Preudhomme, Mauricette Michalet, Francois-Xavier Mahon, Michel Thuilliez, Francois Guilhot, Catherine Roche-Lestienne
Journal: Blood (2004)
SP0184 Paget's Disease: New Developments
Authors: S.H. Ralston
Journal: Annals of the Rheumatic Diseases (2016)

Paget9s disease of bone (PDB) is a common skeletal disorder characterised by increased and disorganised bone remodelling affecting one or bone skeletal sites. Although about 20% of patients that come to clinical attention are asymptomatic others develop complications including bone pain, deformity, nerve compression syndromes and fragility fractures. Genetic factors play an important role in the pathogenesis of PDB and there is strong evidence that susceptibility is determined by variants within or close to genes that regulate osteoclast function. At the present time eight predisposing genes and loci have been discovered. Environmental factors also play a key role but little is known about the nature of these triggers. Bisphosphonates are a highly effective treatment for the elevations in bone turnover that are characteristic of PDB and are effective in the treatment of bone pain associated with Paget9s disease but current evidence sugegsts that they do not prevent complications at least when administered to patients with established disease. Studies are currently in progress to determine if prophylactic treatment of patients with early asymptomatic disease might yield benefits in preventing the development of new lesions and perventing long term complications. <h3>Disclosure of Interest</h3> None declared
Myeloid-derived suppressor cell-like fibrocytes are increased and associated with preserved lung function in chronic obstructive pulmonary disease
Authors: A. K. A. Wright, C. Newby, R. A. Hartley, V. Mistry, S. Gupta, R. Berair, K. M. Roach, R. Saunders, T. Thornton, M. Shelley, K. Edwards, B. Barker, C. E. Brightling
Journal: Allergy (2016)

The role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown. We sought to enumerate blood and tissue fibrocytes in COPD and determine the association of blood fibrocytes with clinical features of disease.Utilizing flow cytometry to identify circulating, collagen type 1+ cells, we found two populations: (i) CD45+ CD34+ (fibrocytes) and (ii) CD45+ CD34- [myeloid-derived suppressor cell (MDSC)-like fibrocytes] cells in stable COPD (n = 41) and control (n = 29) subjects. Lung resection material from a separate group of subjects with (n = 11) or without (n = 11) COPD was collected for tissue fibrocyte detection. We examined circulating fibrocyte populations for correlations with clinical parameters including quantitative computed tomography (qCT) and determined pathways of association between correlated variables using a path analysis model.Blood and tissue fibrocytes were not increased compared to control subjects nor were blood fibrocytes associated with lung function or qCT, but were increased in eosinophilic COPD. Myeloid-derived suppressor cell-like fibrocytes were increased in COPD compared to controls [2.3 (1.1-4.9), P = 0.038]. Our path analysis model showed that collagen type 1 intensity for MDSC-like fibrocytes was positively associated with lung function through associations with air trapping, predominately in the upper lobes.We have demonstrated that two circulating populations of fibrocyte exist in COPD, with distinct clinical associations, but are not prevalent in proximal or small airway tissue. Blood MDSC-like fibrocytes, however, are increased and associated with preserved lung function through a small airway-dependent mechanism in COPD.
TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients
Authors: Craig C Hofmeister, Jesus G. Berdeja, David H. Vesole, Attaya Suvannasankha, Tracy Parrott, Rafat Abonour
Journal: Blood (2015)
Abstract P157: Specific Dietary Fats in Relation to Total and Cause-specific Mortality
Authors: Dong D Wang, Yanping Li, Stephanie E Chiuve, Meir J Stampfer, JoAnn E Manson, Eric B Rimm, Walter C Willett, Frank B Hu
Journal: Circulation (2016)

Introduction: Previous studies have shown distinct associations between specific types of dietary fat and cardiovascular disease. However, studies of specific types of fat in relation to total and cause-specific mortality remain limited and inconsistent. Hypothesis: We hypothesized that specific types of dietary fat were differentially associated with total and cause-specific mortality. Methods: We investigated 83,349 women from the Nurses’ Health Study (1980-2012) and 42,884 men from the Health Professionals Follow-up Study (1986-2012) who were free from cardiovascular disease, cancer and diabetes at baseline. Dietary fat intake was assessed at baseline and updated every 2 to 4 years. Results: We documented 33,304 deaths during 3,439,954 person-years of follow-up. After adjustment for known and suspected risk factors, the hazard ratios (HRs) of total mortality comparing extreme quintiles of intake was 1.08, (95% confidence interval (CI), 1.03-1.14) for saturated fat, 0.81 (95% CI, 0.78-0.84) for polyunsaturated fat, 0.89 (95% CI, 0.84-0.94) for monounsaturated fat and 1.13 (95% CI, 1.07-1.18) for trans fat (P for trend &lt;0.01 for all). Saturated fat intake was associated with a non-significant higher cardiovascular disease mortality across quintiles, while trans fat intake was associated a 20% higher cardiovascular disease mortality across quintiles. Dietary polyunsaturated and monounsaturated fats were each inversely associated with the risk of cardiovascular disease mortality. Replacing 5% of energy from saturated fats with equivalent energy from polyunsaturated fats and monounsaturated fats was associated with 26% (HR =0.74, 95% CI, 0.70-0.77) and 13% (HR =0.87, 95% CI, 0.82-0.92) lower total mortality, respectively. Replacing saturated fats with equivalent energy from polyunsaturated fats and monounsaturated fats was associated with lower risk of mortality due to cardiovascular disease, cancer and neurodegenerative disease. Intake of n-6 polyunsaturated fat, especially linoleic acid, was inversely associated with mortality due to most major causes, while marine n-3 polyunsaturated fat intake was associated with a modestly lower total mortality. Conclusions: Higher saturated fat intake was associated with higher mortality, whereas dietary polyunsaturated fat and monounsaturated fat intakes were inversely associated with mortality. These findings support current dietary recommendations to replace saturated fat with unsaturated fats.
Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.
Authors: Luis Felipe Casado, Isabel Massague, Pilar Giraldo, Manuel Pérez-Encinas, Raquel de Paz, Joaquin Martínez-López, Rafael Fores, Santiago Osorio, Maria José Requena, Luis Palomera, María Jesus Peñarrubia, Carmen Burgaleta, Begoña Maestro, Juan Luis Steegmann
Journal: Blood (2009)
Abstract 3252: LGR5 suppresses colon cancer metastasis
Authors: Xiaolin Zhou, Jing Jenny Wang
Journal: Cancer Research (2015)

Abstract Metastasis is the major cause of death for patients with solid tumors, mainly due to the lack of effective therapies once metastases begin to form. Further research into the mechanism of metastasis is therefore essential in order to have a better understanding of this process and eventually develop more efficient cancer therapies to prevent or treat metastasis. LGR5 is a leucin-rich G protein coupled receptor and a Wnt target gene. It marks the proliferating adult stem cells in the small intestine and has been shown to play an important role in the maintenance of intestine stem cell proliferation by enhancing the canonical Wnt signaling. It is overexpressed in human colorectal, ovary and liver tumors due to the inappropriate activation of Wnt signaling at the onset of those diseases. Recent studies are conflicting regarding the functional role of LGR5 in colon cancer initiation. However, its role in colon cancer progression and metastasis has not been studied. Analysis of copy number variation (CNV) of LGR5 from the Cancer Genome Atlas (TCGA) database revealed that CNV loss of LGR5 is enriched in late stage colon cancer (stage III and IV) with high lymph node spread and/or distant metastasis and in patients with recurrence whereas CNV gain is enriched in early stage disease with no regional or distant metastasis. These results suggest that LGR5 expression may increase during the onset of colon tumorigenesis and decrease thereafter during tumor progression. Functional studies showed that knockdown of LGR5 expression in colon cancer cells increased their clonogenecity, survival capacity and motility in vitro and metastatic dissemination to the liver and lungs in an orthotopic model in vivo. Our results demonstrate that LGR5 functions as a suppressor of colon cancer metastasis and that reduction of LGR5 expression contributes to colon cancer progression and metastasis. Citation Format: Xiaolin Zhou, Jing Jenny Wang. LGR5 suppresses colon cancer metastasis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3252. doi:10.1158/1538-7445.AM2015-3252
ATCT-11RECURRENT GANGLIOGLIOMA TREATED WITH BRAF INHIBITORS
Authors: Marc Chamberlain
Journal: Neuro-Oncology (2015)

BACKGROUND: A mutation in the BRAF oncogene, BRAF V600E has been characterized as commonly present in melanoma as well as a variety of WHO Grade I gliomas including gangliogliomas wherein the mutation is present in approximately 30%.The presence of the BRAF V600E mutation in gangliogliomas suggests the possibility that use of small molecule BRAF inhibitors may have efficacy in the recurrent setting.PATIENTS AND
The computer may be assessing you now, but who decided its values?
Authors: Paul K Hodgkin
Journal: BMJ (2016)

Machine learning holds great promise for medicine,1 but to assess its reliability we need to know what goals the machines have been directed to fulfil and whose values they represent. As Tim O’Reilly (originator of the term “web 2.0”) said in a recent blog, “Understanding how to evaluate algorithms without knowing the exact rules they follow is a …
Evaluation of the Expression of MDM2 &amp; CD44v6 in Hodgkin’s Lymphoma.
Authors: Amr Farag El-Sebaaie, Samya Ahmed Youssef, Osama Abed El-Fatah Hassan, Hala Adel Aggina, Nehal Saad Zafer, Mahmoud Slah Abed El-Slam
Journal: Blood (2007)
Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD.
Authors: Shimon Slavin, Reuven Or, Memet Aker, Michael Y. Shapira, Igor B. Resnick, Menachem Bitan, Svetlana Miron, Irina Zilberman, Simcha Samuel, Yael Gelfand, Corinne Nabet, Osnat Isaacs, Aliza Ackerstein, Shoshana Morecki
Journal: Blood (2004)
The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Jonathan Peled, Eric R. Littman, Lilan Ling, Satyajit Kosuri, Molly Maloy, Sergio A. Giralt, Juliet N. Barker, Miguel-Angel Perales, Ying Taur, Eric Pamer, Marcel van den Brink, Robert R. Jenq
Journal: Blood (2015)
PWE-105 Management of The Malignant Colorectal Polyp: Changes in Practice and Outcomes in A Tertiary Referral Centre in London: Abstract PWE-105 Table 1
Authors: I Parisi, M Mitchison, M Rodriguez-Justo, S McCartney, S Bloom, E Seward, R Vega
Journal: Gut (2016)

<h3>Introduction</h3> Screening colonoscopy has resulted in increasing identification rates of colorectal polyps which can be endoscopically removed. Almost 10% will histologically prove to be pT1 cancers. Factors associated with cancer recurrence post polypectomy have been described (ie lymphovascular invasion, poor differentiation, R1 &lt;1 mm resection margins) and completion surgery is advocated for high risk patients. Since current data are not evidence-based and surgery may implicate significant morbidity, it is of utmost importance to clarify the cost-benefit of each therapeutic option. <h3>Methods</h3> Patients with pT1 cancers that had either endotherapy+surgery or endotherapy alone between 2008–2014 were included in the study (n = 61). Endoscopic, histologic and surgery data, including complication rates from both modalities and overall/ cancer-free survival were recorded. Management was compared between two different periods (2008–11, 2012–14) in order to identify changes in practice. <h3>Results</h3> 38 (62%) patients were treated with endoscopic resection alone. 23 had a completion surgery, 15 (65%) due to R1 resection. Adenomatous tissue was found in 6 surgical specimens but only one had residual cancer. Major complications occurred in 2 (3%) patients post endoscopy versus 6 (26%) postoperatively (p = 0.044), 2 of whom died. There were no cancer relapses at mean follow up of 41±24 months. 17/31 (55%) patients treated prior to 2012 had surgery compared to 6/30 (20%, p = 0.008) treated in 2012–14. More than one risk factors were apparent in 8 (33%) patients treated with endoscopy only within the last 3 years compared to no one previously (p = 0.017). Out of the overall 38 patients with R1 resection, 14 (74%) had completion surgery between 2008–11 compared to 31% recently treated (p = 0.022). <h3>Conclusion</h3> Endoscopic resection of polyp cancers is a safe and successful therapy with minor complications and recurrence rates similar to surgery. Changing our practice recently in favour of endotherapy alone did not lead to increasing cancer relapses, suggesting that presence of risk factors should not be an absolute indication for surgery, but instead an individualised decision should be made based on combination of factors. <h3>Disclosure of Interest</h3> None Declared
AB0590 Evaluation of Dermal Thickness by Three Different Techniques in Systemic Sclerosis Patients
Authors: B. Ruaro, A. Sulli, S. Paolino, C. Pizzorni, M. Cutolo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Skin involvement is critical for sub-classification of systemic sclerosis into different subsets (1). <h3>Objectives</h3> The aim of this study was to identify possible correlations between modified Rodnan skin score (mRSS), high frequency skin ultrasounds (US) and plicometer skin test (Plicometry) in the evaluation of dermal thickness (DT) in patients with (SSc). <h3>Methods</h3> 63 SSc patients (mean age 63±12SD years, mean SSc duration 6±5 years) and 63 healthy subjects (mean age 65±15SD years) were enrolled. The three methods were employed in the seventeen areas of the skin usually evaluated by mRSS (face, fingers, dorsum of hands, forearms, arms, chest, abdomen, thighs, legs and feet) and the total score calculated, as previously reported (2,3). US was performed by a 18 MHz probe (Esaote, Italy) reporting DT as millimetres, and Plicometry (Gima, Italy) adopting a 0–3 score as for mRSS assessment (4). Nailfold videocapillaroscopy (NVC) was performen in SSc patients to assess the proper pattern of microangiopathy. <h3>Results</h3> A statistically significant positive correlation was found between the three methods to evaluate DT in the SSc patients (mRSS vs US r=0.53, p&lt;0.0001; mRSS vs Plicometry r=0.98, p&lt;0.0001; US vs Plicometry r=0.53, p&lt;0.0001). In particular, US showed that all SSc patients had a statistically significant higher DT in the 17 areas when compared with control subjects (p=0.0001). DT measurements were found progressively higher in patients with "Early", "Active" and "Late" NVC pattern of microangiopathy. <h3>Conclusions</h3> This study demonstrates a significant relationship between mRSS, US and Plicometry in dermal thickness evaluation in SSc patients. At the level of the seventeen skin areas analyzed by US, all SSc patients showed a statistically significant higher DT than controls. <h3>References</h3> LeRoy EC et al. J Rheumatol 2001;28:1573–6. Moore TL, et al. Rheumatology 2003;42:1559–63. Sulli A, et al. Ann Rheum Dis. 2014;69:1140–3. Parodi MN, et al. Br J Rheumatol. 1997;36:244–50. <h3>Disclosure of Interest</h3> None declared
Cost-effectiveness of PCSK9 Inhibitor Therapy
Authors: Vera Mastey, Bryan M. Johnstone
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.
Authors: Stefan Langner, Philipp B. Staber, Armin Zebisch, Wilma Zinke-Cerwenka, Heinz Sill, Werner Linkesch, Hildegard Greinix, Peter Kalhs, Werner Rabitsch, Peter Neumeister
Journal: Blood (2006)
Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia
Authors: Megan Hanna, Bethany Tesar, Kristen E. Stevenson, Alexander R. Vartanov, Stacey M. Fernandes, Laura Macconaill, Dan-Avi Landau, Catherine J. Wu, Donna S. Neuberg, Arnold S. Freedman, Jennifer R. Brown
Journal: Blood (2012)
Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Mismatched Unrelated Donors
Authors: Anna Koclega, Miroslaw Markiewicz, Urszula Siekiera, Alicja Dobrowolska, Sylwia Mizia, Monika Dzierzak-Mietla, Patrycja Zielinska, Malgorzata Sobczyk-Kruszelnicka, Slawomira Kyrcz-Krzemien
Journal: Blood (2012)
Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.
Authors: Saroj Vadhan-Raj, Donna M. Weber, Michael Wang, Sergio A. Giralt, Sheeba K. Thomas, Raymond Alexanian, Xiao Zhou, Priya Patel, Carlos E. Bueso-Ramos, Robert A. Newman, Bharat B. Aggarwal
Journal: Blood (2007)
Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.
Authors: T.M. de Witte, Ronald Brand, Anja van Biezen, Ghulam Mufti, Tapani Ruutu, Jurgen Finke, Peter von dem Borne, Antonin Vitek, Michel Delforge, Paolo E. Alessandrino, Nicholas Harhalakis, Nigel H. Russell, Enric Carreras, Leo F. Verdonck, Dietger W. Niederwieser
Journal: Blood (2006)
Acadesine (Acadra‘) for Patients with Resistant/Relapsed Chronic B-Cell Lymphocytic Leukemia (B-CLL): A Multicentre Phase I/II Study.
Authors: Eric W Van Den Neste, Eva Gonzalez-Barca, Ann Janssens, Bruno Cazin, J. Pérez de Oteyza, Maria Jose Terol, T. Auton, Andrew Saunders, Clara Campas
Journal: Blood (2009)